BioMarin (BMRN) EVP Cristin Hubbard reports 2,318-share tax-withholding disposition
BioMarin Pharmaceutical's EVP, Chief Commercial Officer Cristin Hubbard, reported a tax-related disposition of 2,318 shares of common stock. These shares, valued at $50.20 each, were withheld to cover tax obligations. Following this non-market transaction, Hubbard retains direct ownership of 42,472 shares in the company.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin Pharmaceutical Inc. announced positive Phase 3 results for VOXZOGO® (vosoritide) in children with hypochondroplasia, meeting its primary endpoint with a statistically significant increase in annualized growth velocity. The study also showed improvements in standing height, height Z-score, and arm span, with a safety profile consistent with previous findings. BioMarin plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026.
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
BioMarin Pharmaceutical Inc. (BMRN) announced that its Phase 3 ENERGY 3 trial for BMN 401 in children with ENPP1 deficiency met only one of its two co-primary endpoints. While treatment significantly increased plasma inorganic pyrophosphate concentration, it failed to improve critical measures of rickets severity or other secondary endpoints. The company is evaluating the data to determine next steps, expressing disappointment that increased PPi levels did not translate into clinical benefits.
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
BioMarin Pharmaceutical Inc. announced that its Phase 3 ENERGY 3 trial for BMN 401, targeting ENPP1 deficiency, met only one of its two co-primary endpoints. While treatment significantly increased plasma inorganic pyrophosphate concentration, it failed to improve critical rickets severity scores. The company plans to analyze the data further and present detailed results at an upcoming medical meeting.
BioMarin moves to expand Voxzogo into hypochondroplasia with pivotal win
BioMarin Pharmaceutical's drug Voxzogo achieved positive results in a pivotal Phase 2 trial for hypochondroplasia, a genetic bone growth disorder. The company plans to use this data to seek regulatory approval for Voxzogo in this new indication, beyond its current approval for achondroplasia. This expansion could significantly increase the drug's patient population and market potential.
BioMarin stock surges on positive hypochondroplasia trial data
BioMarin Pharmaceutical (NASDAQ:BMRN) shares rose 4.8% after reporting positive Phase 3 trial results for VOXZOGO in children with hypochondroplasia. The study met its primary endpoint, showing significant improvements in annualized growth velocity, standing height, and arm span. BioMarin plans to submit a supplemental New Drug Application to regulatory bodies in Q3 2026.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin Pharmaceutical Inc. announced positive Phase 3 pivotal study results for VOXZOGO (vosoritide) in children with hypochondroplasia, meeting its primary endpoint with a significant improvement in annualized growth velocity. The study also showed statistically significant increases in standing height, height Z-score, and arm span. BioMarin plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA in the third quarter, followed by submissions to European and other regional health authorities.
BMRN stock down on mixed results from rare disease therapy study
BioMarin Pharmaceutical (BMRN) stock experienced a decline following mixed outcomes from its Phase 1/2 study of BMN 351, an investigational treatment for Duchenne muscular dystrophy. While a higher dose showed promise in reducing sarcolemma damage, the results were not statistically significant enough to alleviate investor concerns, leading to an 8% drop in share price. The company plans to continue with the higher dose in future trials.
BioMarin’s SWOT analysis: rare disease biotech stock faces competitive headwinds
BioMarin Pharmaceutical Inc. is navigating significant clinical setbacks and competitive pressures despite its strong foundation in ultra-rare genetic diseases. The company faces threats to its Voxzogo market share from emerging competitors and experienced a clinical challenge with its ENPP1 pediatric study, though it plans to pivot to adult populations. While BioMarin maintains strong financial health and orphan drug exclusivity offers some protection, analyst downgrades and downward earnings revisions reflect current uncertainties.
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin Pharmaceutical's stock fell 4% after its phase III ENERGY 3 study for BMN 401, an investigational therapy for ENPP1 deficiency, yielded mixed results. While the treatment showed a statistically significant increase in a key biomarker (plasma PPi), it failed to improve Radiographic Global Impression of Change (RGI-C) scores, indicating no measurable skeletal benefits in children with rickets. The company plans further analysis and engagement with regulatory authorities to determine the future of the development program.
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
BioMarin's investigational enzyme replacement therapy, BMN 401, failed to achieve clinical improvements in a Phase 3 study for ENPP1 deficiency, despite showing significant biomarker improvements. This setback follows other recent challenges for BioMarin, including the discontinuation of its hemophilia A gene therapy Roctavian due to underwhelming market performance and safety concerns with its achondroplasia drug Voxzogo. The failure of BMN 401 adds to the pressure on BioMarin as it faces increasing competition for its key products.
H.C. Wainwright cuts BioMarin stock price target after trial miss
H.C. Wainwright has lowered its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $50 from $55, maintaining a Neutral rating, after its BMN 401 drug failed to meet a key clinical endpoint in a Phase 3 trial despite showing a biochemical effect. The drug, intended for ENPP1 deficiency, did not translate increased inorganic pyrophosphate into measurable skeletal benefits in pediatric rickets patients. This downgrade follows BioMarin's recent Q1 2026 earnings beat and other analyst actions, including Goldman Sachs initiating coverage with a Neutral rating and Freedom Broker raising its price target, amidst competitive pressures for its Voxzogo product.
Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50
BioMarin Pharmaceutical's BMN 401 drug raised plasma PPi in children over 52 weeks but did not show significant improvement in rickets or growth. Following this announcement, shares of BMRN fell by approximately 3% to around $50.10. HC Wainwright & Co. consequently reiterated a Neutral rating and lowered its price target from $55.00 to $50.00.
Biomarin stock hits 52-week low at 50.75 USD By Investing.com
BioMarin Pharmaceutical Inc.'s stock (BMRN) has fallen to a 52-week low of $50.66, reflecting a 12.6% decline over the past year. Despite the downturn, analysts see a significant upside potential of 68%, and InvestingPro has given the company a "GREAT" financial health score. The company recently reported better-than-expected Q1 2026 earnings but faced mixed results in a Phase 3 trial, alongside competitive concerns highlighted by analysts.
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
BioMarin Pharmaceutical's $270 million acquisition of Inozyme faces challenges after its lead enzyme replacement therapy, BMN 401, missed one of its dual primary endpoints in a phase 3 study. Despite a statistically significant increase in inorganic pyrophosphate, the drug failed to show skeletal healing improvements in children with ENPP1 deficiency, and no positive trends were observed in secondary endpoints. BioMarin is now evaluating the data to determine the next steps for the candidate.
Rare disease drug lifts blood marker but not rickets severity in children
BioMarin (BMRN) announced top-line Phase 3 trial results for BMN 401 in children with ENPP1 deficiency, revealing a mixed outcome. While the drug significantly increased a key blood marker (plasma PPi), it failed to improve rickets severity or other clinical endpoints. The company is evaluating its next steps for the BMN 401 program.
BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study
BioMarin Pharmaceutical reported that its Phase 3 trial for BMN 401, a treatment for ENPP1 deficiency in children aged 1-12, showed no functional improvement. This news comes amidst other mixed results for BioMarin's genetic disease therapies. The report indicates a significant setback for this particular pipeline candidate.
BioMarin Pharmaceutical stock (US09061G1013): higher 2026 sales outlook puts margins in the spotligh
BioMarin Pharmaceutical has raised its full-year 2026 revenue guidance to US$3.83 billion to US$3.93 billion, despite a slight decline in first-quarter earnings due to increased manufacturing and acquisition costs. The biotech firm's rare-disease portfolio, particularly VOXZOGO, is expected to drive sales, but investors are now scrutinizing the company's ability to improve margins amidst these cost pressures. The article highlights the importance for investors to monitor both clinical milestones and the evolving healthcare policy backdrop.
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised
BioMarin Pharmaceutical reported mixed first-quarter results, with earnings per share and adjusted EPS missing analyst expectations despite a beat on sales. The company reiterated its 2024 revenue and earnings outlook while raising its 2026 revenue guidance for specific products, driven by strong growth in its gene therapy, Roctavian.
What BioMarin Pharmaceutical (BMRN)'s Higher 2026 Sales Outlook and Lower Earnings Guidance Means For Shareholders
BioMarin Pharmaceutical reported a modest increase in first-quarter revenue for 2026, reaching US$766.21 million, but net income and earnings per share declined due to higher manufacturing and acquisition costs. Despite this, the company significantly raised its full-year 2026 revenue guidance to US$3.83 billion to US$3.93 billion, indicating strong demand for its products. The article suggests that while BioMarin has a stronger revenue outlook, investors should monitor how effectively this translates into improved profitability, especially given ongoing margin pressures and increased R&D and integration spending.
BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors
BioMarin Pharmaceutical Inc. (BMRN) is conducting a follow-on study for its Duchenne muscular dystrophy drug BMN 351, focusing on long-term safety and effectiveness. The open-label, interventional study tracks weekly infusions in exon 51-skippable Duchenne patients to confirm lasting safety and functional gains. This extension aims to bolster BMRN's rare disease portfolio and support the drug's future commercialization by collecting crucial long-term data.
Morgan Stanley resumed coverage on BioMarin Pharmaceutical with a new price target
Morgan Stanley has resumed its coverage of BioMarin Pharmaceutical (BMRN) and issued a new price target. This information was alerted to Quantisnow Plus members shortly after publication. Quantisnow provides real-time market data to retail investors, including analyst ratings, SEC filings, and insider trading information for companies like BioMarin.
Evercore ISI Lifts PT on BioMarin Pharmaceutical Inc. (BMRN)
Evercore ISI has raised its price target for BioMarin Pharmaceutical Inc. (BMRN) to $120 from $110, maintaining an Outperform rating. This decision follows recent positive research findings on BMRN's VOXZOGO® treatment, which showed favorable impacts on health indicators in children with achondroplasia and hypochondroplasia, including arm span and bone density. The company is actively developing and commercializing therapies for rare and life-threatening conditions, with its product pipeline including Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer
BioMarin Pharmaceutical is laying off 58 employees at the Amicus Therapeutics headquarters in Princeton, New Jersey, following its $4.8 billion acquisition of the rare disease company. These job cuts are part of an integration process aimed at streamlining operations where there is overlap, leveraging BioMarin's global scale for Amicus's medicines. The layoffs, confirmed by a BioMarin spokesperson, are scheduled to begin in August and conclude by the end of October.
BioMarin Pharmaceutical (BMRN) Valuation Check As 2026 Guidance Rises And VOXZOGO Data Strengthens
BioMarin Pharmaceutical's stock (BMRN) is under valuation scrutiny despite raised 2026 revenue guidance to US$3.83b-$3.93b and positive VOXZOGO data. While a narrative fair value suggests the stock is 39.2% undervalued at $88.87, its high P/E ratio of 38.9x (compared to the US Biotechs average of 17.7x) indicates potential valuation risk. The article advises investors to review the numbers and consider both rewards and warning signs before making a decision.
California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
BioMarin Pharmaceuticals Inc. released long-term data for its drug VOXZOGO, showing positive effects on patients with achondroplasia, including improved arm span and bone density. The company also reported Q1 2026 financial results with total revenues of US$766 million, an increase from 2025, driven by enzyme therapies and VOXZOGO sales, despite a decrease in GAAP and Non-GAAP net income. Analysts offered mixed ratings, with some projecting significant price target increases due to new acquisitions and pipeline advancements.
The Technical Signals Behind (BMRN) That Institutions Follow
This article analyzes the technical signals for BioMarin Pharmaceutical Inc. (BMRN), highlighting weak near-term sentiment and a mid-channel oscillation pattern. It presents an exceptional 28.4:1 risk-reward setup, targeting an 8.2% gain against 0.3% risk. The piece also details institutional trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis.
BioMarin (BMRN) R&D chief Friberg sells 3,281 shares in open-market trade
BioMarin Pharmaceutical's EVP and Chief R&D Officer, Gregory R. Friberg, sold 3,281 shares of common stock at $53.85 per share in an open-market transaction on May 7, 2026. Following this sale, Friberg directly holds 51,818 shares. The sale is considered moderate and likely for routine liquidity or portfolio management, rather than a significant change in outlook.
Goldman Sachs initiates BioMarin stock coverage at neutral on competitive concerns
Goldman Sachs has initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a Neutral rating and a $69.00 price target, citing competitive concerns despite the stock being undervalued by InvestingPro data. The firm noted potential threats to BioMarin's drug Voxzogo from competitors like BridgeBio Pharma and expects a compound annual decline in achondroplasia sales from 2027 to 2035. Despite strong first-quarter 2026 earnings that beat expectations, the stock declined in after-hours trading.
Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips
BioMarin Pharmaceutical Inc. (BMRN) reported Q1 2026 earnings per share and revenue that exceeded analyst forecasts, despite which its stock dipped by 1.52% in after-hours trading. The company's performance was bolstered by robust demand for enzyme therapies and the Voxzogo segment, and its full-year guidance was raised, incorporating the recently completed acquisition of Amicus Pharmaceuticals, which is expected to be accretive to EPS starting in 2027. Executives also provided updates on clinical trials and addressed concerns about geopolitical uncertainties and the Amicus integration roadmap.
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Its Multi‑Year Share Price Slide
BioMarin Pharmaceutical (BMRN) has experienced significant share price declines over multiple years, prompting a reassessment of its valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is 72% undervalued, trading at $54.12 against an estimated intrinsic value of $193.36, its current P/E ratio of 38.92x is significantly higher than the biotech industry average, indicating it might be overvalued based on earnings. Investors can utilize Simply Wall St's "Narratives" feature to create personalized valuation models considering various factors and risks.
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised
BioMarin Pharmaceutical (BMRN) reported Q1 earnings that missed analyst estimates but exceeded sales expectations, driven by strong growth in its key products. The company also raised its revenue guidance for 2026, signaling confidence in its pipeline and market position.
BioMarin Pharmaceutical Q1 profit falls 43% on higher drug manufacturing and acquisition costs
BioMarin Pharmaceutical reported a 43% drop in first-quarter net income due to increased manufacturing and acquisition costs, despite a rise in overall revenue. The company's earnings per share fell significantly below analyst expectations. However, demand for several treatments for rare genetic disorders is growing, and BioMarin raised its full-year 2026 revenue forecast following its $4.8 billion acquisition of Amicus Therapeutics, which added new medicines to its portfolio.
BioMarin Pharmaceutical Price Target Raised to $116.00/Share From $104.00 by Canaccord Genuity
Canaccord Genuity has raised its price target for BioMarin Pharmaceutical to $116.00 per share, up from the previous target of $104.00. This adjustment indicates a more optimistic outlook on the company's future performance by the investment firm.
BMRN (NASDAQ) Form 144: 3,281 shares via Fidelity on 05/07/2026
BioMarin Pharmaceutical Inc. (BMRN) submitted a Form 144 notice on May 7, 2026, detailing the proposed sale of 3,281 common shares through Fidelity Brokerage Services LLC, valued at $176,682.18. The filing also mentions recent restricted stock vesting of 2,808 shares and an ESPP purchase of 473 shares. Additionally, it highlights a past sale by Gregory Friberg of 6,326 shares on February 26, 2026, for $381,937.07.
BioMarin (NASDAQ: BMRN) Q1 profit drops as $4.8B Amicus acquisition ramps
BioMarin Pharmaceutical Inc. reported a significant drop in Q1 2026 net income to $105.5 million from $185.7 million in Q1 2025, primarily due to increased operating expenses, including a $31.0 million charge for an unsuccessful NAGLAZYME manufacturing campaign and higher SG&A/R&D costs. This occurred as the company finalized its $4.8 billion all-cash acquisition of Amicus Therapeutics, which diversified BioMarin's rare disease portfolio but also substantially increased its debt obligations. Despite the profit decline, total revenues modestly rose to $766.2 million, driven by strong sales of VOXZOGO and other enzyme therapies, although ROCTAVIAN sales decreased following its voluntary market withdrawal.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) held its Q1 2026 earnings call, reporting an EPS miss at $0.54 against expectations of $0.94. The company highlighted the recent acquisition of Amicus, which is expected to accelerate year-over-year revenue growth to 20% at the midpoint of updated guidance, largely driven by Galafold for Fabry disease and Pombility/Opfolda for Pompe disease. BioMarin also provided updates on strong patient demand for Voxzogo across all regions and ages, progress in its pipeline with significant data readouts expected in Q2 2026 for hypochondroplasia and ENPP1 deficiency, and ongoing efforts to integrate Amicus and expand its commercial portfolio.
BioMarin Pharmaceutical Q1 2026: $0.76 EPS Falls Short — Deep Dive
BioMarin Pharmaceutical's Q1 2026 results showed a revenue beat of 1.8% but an adjusted EPS of $0.76 that missed estimates by 20.8%, with net income plummeting by over half compared to Q1 2025. Despite a 20% increase in patient volume for its VOXZOGO franchise, revenue growth was only 3%, raising concerns about pricing or payer mix. The company's raised full-year guidance relies heavily on acquisition-driven growth rather than organic momentum.
Earnings call transcript: BioMarin Q1 2026 beats EPS forecasts, stock dips slightly
BioMarin Pharmaceutical Inc. exceeded Q1 2026 EPS and revenue forecasts, reporting EPS of $0.76 against an expected $0.74, and revenue of $766 million against a forecast of $755.94 million. Despite these positive financial results, the stock saw a slight decline of 0.13% in aftermarket trading. The company updated its full-year revenue guidance to between $3.825 billion and $3.925 billion, expecting significant growth driven by strong demand for enzyme therapies and the recent Amicus acquisition.
BioMarin Pharmaceutical Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for BioMarin Pharmaceutical. It anticipates the upcoming financial results for the company.
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call
BioMarin Pharmaceutical (BMRN) reported Q1 2026 revenues of $766 million and raised its full-year guidance to $3.825-$3.925 billion, driven by the acquisition of Amicus and strong performance of enzyme therapies and Voxogo. The company's immediate focus is on integrating Amicus products to accelerate growth, expecting higher revenues and profitability in the second half of 2026. Key pipeline updates include pivotal data for Voxogo in hypochondroplasia and BMN401 for ENPP1 deficiency, both expected in Q2 2026.
BioMarin: Q1 Earnings Snapshot
BioMarin Pharmaceutical Inc. (BMRN) reported first-quarter earnings of $105.5 million, or 54 cents per share, which adjusted to 76 cents per share. This fell short of analyst expectations of 94 cents per share. The company's revenue of $766.2 million, however, exceeded Street forecasts, and it provided full-year earnings guidance between $4.85 and $5.05 per share, with revenue projections of $3.83 billion to $3.93 billion.
BioMarin: Q1 Earnings Snapshot
BioMarin Pharmaceutical Inc. reported first-quarter earnings of $105.5 million, or 54 cents per share, which adjusted to 76 cents per share. This fell short of Wall Street's expectation of 94 cents per share. However, the company's revenue of $766.2 million surpassed forecasts, and BioMarin provided full-year earnings and revenue guidance.
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91
BioMarin Pharmaceutical Inc. (BMRN) reported Q1 adjusted EPS of $0.76 per share, falling short of the FactSet estimate of $0.91 per share. This financial update indicates underperformance compared to analyst expectations for the quarter. The company also recently provided its full-year 2026 guidance for revenue and adjusted EPS.
BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal
BioMarin Pharmaceutical Inc. reported its first-quarter 2026 results and significantly raised its full-year 2026 revenue outlook due to the Amicus acquisition, which added GALAFOLD and POMBILITI + OPFOLDA to its portfolio. While total revenues increased by 3% year-over-year, GAAP and Non-GAAP net income decreased due to higher operating and manufacturing costs, including a $31 million NAGLAZYME charge. The company now expects 2026 total revenue between $3.825–$3.925 billion but slightly lowered its Non-GAAP diluted EPS guidance to $4.85–$5.05.
Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia
BioMarin Pharmaceutical Inc. has released new data regarding the long-term impact of its drug, Voxzogo (vosoritide), on children suffering from achondroplasia. The study focuses on how the treatment affects arm span, overall bone health, and growth development in these children. More detailed information requires registration on the MarketScreener website.
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
BioMarin Pharmaceutical (BMRN) is set to report its earnings on Monday afternoon. Analysts expect a 4.1% year-on-year revenue growth, slowing from the previous year, despite the company missing revenue estimates multiple times in the last two years. While the therapeutics segment overall has shown positive investor sentiment, BioMarin Pharmaceutical's stock is down 3.8% over the last month, heading into earnings with an average analyst price target significantly higher than its current share price.
Six-year study finds bone health maintained in children on VOXZOGO
BioMarin (Nasdaq: BMRN) presented new data at the Pediatric Endocrine Society's 2026 Annual Meeting, showing that long-term treatment with VOXZOGO (vosoritide) in children with achondroplasia improved arm span Z-scores, maintained arm span-to-height proportionality, and preserved bone mineral density while increasing bone mineral content. Children who started treatment after age 5 showed significant height gains of 10.60 cm at six years and 13.59 cm at eight years compared to untreated cohorts. Additionally, the company expects topline Phase 3 results for hypochondroplasia in the first half of 2026, with studies already showing statistically significant improvements in total body minus head BMD and BMC in hypochondroplasia patients.
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in BioMarin Pharmaceutical Inc. by 2.4% in Q4, selling over 450,000 shares but still owning 9.44% of the company. Additionally, two EVPs, Gregory R. Friberg and Charles Greg Guyer, recently sold a significant number of their shares. Despite these sales, analysts maintain a "Moderate Buy" rating with an average price target of $91.48, significantly higher than its current share price.
BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a share - Earnings Preview
BioMarin Pharmaceutical Inc (BMRN) is projected to report earnings of 79 cents per share. This information is provided as an earnings preview by Refinitiv. The article is a brief news piece from Reuters via TradingView.
